Initial Statement of Beneficial Ownership (3)
14 January 2022 - 8:43AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Mammen Mathai |
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/3/2022
|
3. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [JNJ]
|
|
(Last)
(First)
(Middle)
ONE JOHNSON & JOHNSON PLAZA |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP, Pharm, R&D / |
|
(Street)
NEW BRUNSWICK, NJ 08933
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Common Stock | 32477.0000 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Employee Stock Options (Right to Buy) (1) | 2/12/2021 | 2/11/2028 | Common Stock | 28927.0000 | $129.5100 | D | |
| Employee Stock Options (Right to Buy) (1) | 2/11/2022 | 2/11/2029 | Common Stock | 36098.0000 | $131.9400 | D | |
| Employee Stock Options (Right to Buy) (1) | 2/10/2023 | 2/10/2030 | Common Stock | 58130.0000 | $151.4100 | D | |
| Employee Stock Options (Right to Buy) (1) | 2/28/2024 | 2/28/2031 | Common Stock | 43149.0000 | $164.6200 | D | |
| Restricted Share Units (2) | 2/3/2023 | (2) | Common Stock | 35951.0000 | (2) | D | |
| Restricted Share Units (2) | 2/8/2024 | (2) | Common Stock | 3929.0000 | (2) | D | |
| Restricted Share Units (2) | 2/10/2023 | (2) | Common Stock | 4545.0000 | (2) | D | |
| Restricted Share Units (2) | 2/11/2022 | (2) | Common Stock | 7418.0000 | (2) | D | |
| Explanation of Responses: |
| (1) | Vested and exercisable on the third anniversary of the date of the grant. |
| (2) | Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Mammen Mathai
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933 |
|
| EVP, Pharm, R&D |
|
Signatures
|
| Raavi Deol, as attorney-in-fact for Mathai Mammen | | 1/13/2022 |
| **Signature of Reporting Person | Date |
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
